Skip to main content
Erschienen in: Endocrine 2/2015

01.03.2015 | Original Article

Fibroblast growth factor 21 expressions in white blood cells and sera of patients with gestational diabetes mellitus during gestation and postpartum

verfasst von: Si-ming Li, Wen-fei Wang, Li-hong Zhou, Lei Ma, Ying An, Wen-juan Xu, Tian-he Li, Yin-hang Yu, De-shan Li, Yan Liu

Erschienen in: Endocrine | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Fibroblast growth factor 21 (FGF21), a recently discovered regulatory factor, plays an important role in glucose and lipid metabolism. In this study, we firstly found the FGF21 expression in white blood cells (WBCs). Then, we enrolled 51 women with gestational diabetes mellitus (GDM) and 50 pregnant women with normal blood glucose levels to determine the FGF21 levels in the WBCs and the sera at the 28th week of pregnancy, and tracked the dynamic changes of FGF21 in these women until the 7th day postpartum. Repeated Measures analysis of variance (ANOVA) revealed that there was a significant interaction effect between group and time on FGF21 levels (P < 0.05). FGF21 levels were significantly higher in the GDM patients than those in the controls at the 28th week of pregnancy. The 7th day after the delivery, the FGF21 levels decreased in the WBCs and the sera in both groups. The D values (the difference between pregnancy and postpartum) for FGF21 levels were significantly higher in the GDM group (P < 0.05). Serum FGF21 level during gestation positively correlated with leptin, triglyceride, and HDL-cholesterol, and FGF21 may act as a glucose and lipid metabolism compensatory regulatory factor to improve glucose and lipid metabolism during the period of pregnancy. Further, FGF21 level in the WBCs (during pregnancy and the D values for FGF21) was chiefly influenced by GDM.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat International Association of Diabetes and Pregnancy Study Groups Consensus Panel, B.E. Metzger, S.G. Gabbe, B. Persson, T.A. Buchanan, P.A. Catalano et al., International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 33, 676–682 (2010)CrossRefPubMedCentral International Association of Diabetes and Pregnancy Study Groups Consensus Panel, B.E. Metzger, S.G. Gabbe, B. Persson, T.A. Buchanan, P.A. Catalano et al., International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 33, 676–682 (2010)CrossRefPubMedCentral
3.
Zurück zum Zitat HAPO Study Cooperative Research Group, B.E. Metzger, L.P. Lowe, A.R. Dyer, E.R. Trimble, U. Chaovarindr et al., Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 358, 1991–2002 (2008)CrossRef HAPO Study Cooperative Research Group, B.E. Metzger, L.P. Lowe, A.R. Dyer, E.R. Trimble, U. Chaovarindr et al., Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 358, 1991–2002 (2008)CrossRef
4.
Zurück zum Zitat B.L. Silverman, T.A. Rizzo, N.H. Cho, B.E. Metzger, Long-term effects of the intrauterine environment. The Northwestern University Diabetes in Pregnancy Center. Diabetes Care 21, B142–B149 (1998)PubMed B.L. Silverman, T.A. Rizzo, N.H. Cho, B.E. Metzger, Long-term effects of the intrauterine environment. The Northwestern University Diabetes in Pregnancy Center. Diabetes Care 21, B142–B149 (1998)PubMed
5.
Zurück zum Zitat P.M. Catalano, J.P. Kirwan, S.M. De Haugel, J. King, Gestational diabetes and insulin resistance: role in short- and long-term implications for mother and fetus. J Nutr. 133(5), 1674S–1683S (2003)PubMed P.M. Catalano, J.P. Kirwan, S.M. De Haugel, J. King, Gestational diabetes and insulin resistance: role in short- and long-term implications for mother and fetus. J Nutr. 133(5), 1674S–1683S (2003)PubMed
6.
Zurück zum Zitat N.A. Beischer, P. Wein, M.T. Sheedy, B. Steffen, Identification and treatment of women with hyperglycaemia diagnosed during pregnancy can significantly reduce perinatal mortality rates. Aust. N. Z. J. Obstet. Gynaecol. 36(3), 239–247 (1996)CrossRefPubMed N.A. Beischer, P. Wein, M.T. Sheedy, B. Steffen, Identification and treatment of women with hyperglycaemia diagnosed during pregnancy can significantly reduce perinatal mortality rates. Aust. N. Z. J. Obstet. Gynaecol. 36(3), 239–247 (1996)CrossRefPubMed
7.
Zurück zum Zitat A.J. Lee, R.J. Hiscock, P. Wein, S.P. Walker, M. Permezel, Gestational diabetes mellitus: clinical predictors and long-term risk of developing type 2 diabetes: a retrospective cohort study using survival analysis. Diabetes Care 30, 878–883 (2007)CrossRefPubMed A.J. Lee, R.J. Hiscock, P. Wein, S.P. Walker, M. Permezel, Gestational diabetes mellitus: clinical predictors and long-term risk of developing type 2 diabetes: a retrospective cohort study using survival analysis. Diabetes Care 30, 878–883 (2007)CrossRefPubMed
8.
Zurück zum Zitat D.J. Pettitt, R.G. Nelson, M.F. Saad, P.H. Bennett, W.C. Knowler, Diabetes and obesity in the offspring of Pima Indian women with diabetes during pregnancy. Diabetes Care 16(1), 310–314 (1993)CrossRefPubMed D.J. Pettitt, R.G. Nelson, M.F. Saad, P.H. Bennett, W.C. Knowler, Diabetes and obesity in the offspring of Pima Indian women with diabetes during pregnancy. Diabetes Care 16(1), 310–314 (1993)CrossRefPubMed
9.
Zurück zum Zitat C. Kim, K.M. Newton, R.H. Knopp, Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 25(10), 1862–1868 (2002)CrossRefPubMed C. Kim, K.M. Newton, R.H. Knopp, Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 25(10), 1862–1868 (2002)CrossRefPubMed
10.
Zurück zum Zitat T. Nishimura, Y. Nakatake, M. Konishi, N. Itoh, Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta 1492(1), 203–206 (2000)CrossRefPubMed T. Nishimura, Y. Nakatake, M. Konishi, N. Itoh, Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta 1492(1), 203–206 (2000)CrossRefPubMed
11.
Zurück zum Zitat M.D. Chau, J. Gao, Q. Yang, Z. Wu, J. Gromada, Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc Natl Acad Sci U S A. 107, 12553–12558 (2010)CrossRefPubMedCentralPubMed M.D. Chau, J. Gao, Q. Yang, Z. Wu, J. Gromada, Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc Natl Acad Sci U S A. 107, 12553–12558 (2010)CrossRefPubMedCentralPubMed
12.
Zurück zum Zitat B. Matuszek, M. Lenart-Lipińska, D. Duma, J. Solski, A. Nowakowski, Evaluation of concentrations of FGF-21-a new adipocytokine in type 2 diabetes. Endokrynol Pol. 61(1), 50–54 (2010)PubMed B. Matuszek, M. Lenart-Lipińska, D. Duma, J. Solski, A. Nowakowski, Evaluation of concentrations of FGF-21-a new adipocytokine in type 2 diabetes. Endokrynol Pol. 61(1), 50–54 (2010)PubMed
13.
Zurück zum Zitat Y. Zhao, J.D. Dunbar, A. Kharitonenkov, FGF21 as a therapeutic reagent. Adv. Exp. Med. Biol. 728, 214–228 (2012)CrossRefPubMed Y. Zhao, J.D. Dunbar, A. Kharitonenkov, FGF21 as a therapeutic reagent. Adv. Exp. Med. Biol. 728, 214–228 (2012)CrossRefPubMed
14.
Zurück zum Zitat A. Kharitonenkov, V.J. Wroblewski, A. Koester, Y.F. Chen, C.K. Clutinger, X.T. Tigno et al., The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148(2), 774–781 (2007)CrossRefPubMed A. Kharitonenkov, V.J. Wroblewski, A. Koester, Y.F. Chen, C.K. Clutinger, X.T. Tigno et al., The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148(2), 774–781 (2007)CrossRefPubMed
15.
Zurück zum Zitat T. Coskun, H.A. Bina, M.A. Schneider, J.D. Dunbar, C.C. Hu, Y. Chen et al., Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149(12), 6018–6027 (2008)CrossRefPubMed T. Coskun, H.A. Bina, M.A. Schneider, J.D. Dunbar, C.C. Hu, Y. Chen et al., Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149(12), 6018–6027 (2008)CrossRefPubMed
16.
Zurück zum Zitat J. Xu, D.J. Lloyd, C. Hale, S. Stanislaus, M. Chen, G. Sivits et al., Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58(1), 250–259 (2009)CrossRefPubMedCentralPubMed J. Xu, D.J. Lloyd, C. Hale, S. Stanislaus, M. Chen, G. Sivits et al., Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58(1), 250–259 (2009)CrossRefPubMedCentralPubMed
17.
Zurück zum Zitat S. Stein, H. Stepan, J. Kratzsch, M. Verlohren, H.J. Verlohren, K. Drynda et al., Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia. Metabolism 59(1), 33–37 (2010)CrossRefPubMed S. Stein, H. Stepan, J. Kratzsch, M. Verlohren, H.J. Verlohren, K. Drynda et al., Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia. Metabolism 59(1), 33–37 (2010)CrossRefPubMed
18.
Zurück zum Zitat B.K. Tan, K. Sivakumar, M.F. Bari, M. Vatish, H.S. Randeva, Lower cerebrospinal fluid/plasma fibroblast growth factor 21 (FGF21) ratios and placental FGF21 production in gestational diabetes. PLoS ONE 8(6), e65254 (2013)CrossRefPubMedCentralPubMed B.K. Tan, K. Sivakumar, M.F. Bari, M. Vatish, H.S. Randeva, Lower cerebrospinal fluid/plasma fibroblast growth factor 21 (FGF21) ratios and placental FGF21 production in gestational diabetes. PLoS ONE 8(6), e65254 (2013)CrossRefPubMedCentralPubMed
20.
Zurück zum Zitat T.A. Buchanan, A. Xiang, S.L. Kjos, R. Watanabe, What is gestational diabetes? Diabetes Care 30, S105–S111 (2007)CrossRefPubMed T.A. Buchanan, A. Xiang, S.L. Kjos, R. Watanabe, What is gestational diabetes? Diabetes Care 30, S105–S111 (2007)CrossRefPubMed
21.
Zurück zum Zitat W.W. Chen, L. Li, G.Y. Yang, K. Li, X.Y. Qi, W. Zhu et al., Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 116(1), 65–68 (2008)CrossRefPubMed W.W. Chen, L. Li, G.Y. Yang, K. Li, X.Y. Qi, W. Zhu et al., Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 116(1), 65–68 (2008)CrossRefPubMed
22.
Zurück zum Zitat X. Zhang, D.C. Yeung, M. Karpisek, D. Stejskal, Z.G. Zhou, F. Liu et al., Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57(5), 1246–1253 (2008)CrossRefPubMed X. Zhang, D.C. Yeung, M. Karpisek, D. Stejskal, Z.G. Zhou, F. Liu et al., Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57(5), 1246–1253 (2008)CrossRefPubMed
23.
Zurück zum Zitat A.O. Chavez, M. Molina-Carrion, M.A. Abdul-Ghani, F. Folli, R.A. Defronzo, D. Tripathy, Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 32(8), 1542–1546 (2009)CrossRefPubMedCentralPubMed A.O. Chavez, M. Molina-Carrion, M.A. Abdul-Ghani, F. Folli, R.A. Defronzo, D. Tripathy, Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 32(8), 1542–1546 (2009)CrossRefPubMedCentralPubMed
24.
Zurück zum Zitat S. Stein, A. Bachmann, U. Lössner, J. Kratzsch, M. Blüher, M. Stumvoll et al., Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care 32(1), 126–128 (2009)CrossRefPubMedCentralPubMed S. Stein, A. Bachmann, U. Lössner, J. Kratzsch, M. Blüher, M. Stumvoll et al., Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care 32(1), 126–128 (2009)CrossRefPubMedCentralPubMed
25.
Zurück zum Zitat Nitert MD1, Barrett HL, Kubala MH, Scholz Romero K, Denny KJ, Woodruff TM, et al. Increased placental expression of Fibroblast Growth Factor 21 in gestational diabetes mellitus. J Clin Endocrinol Metab. 2014 Jan 16:jc20132581. [Epub ahead of print] Nitert MD1, Barrett HL, Kubala MH, Scholz Romero K, Denny KJ, Woodruff TM, et al. Increased placental expression of Fibroblast Growth Factor 21 in gestational diabetes mellitus. J Clin Endocrinol Metab. 2014 Jan 16:jc20132581. [Epub ahead of print]
26.
Zurück zum Zitat N.F. Butte, Carbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus. Am. J. Clin. Nutr. 71(5), 1256S–1261S (2000)PubMed N.F. Butte, Carbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus. Am. J. Clin. Nutr. 71(5), 1256S–1261S (2000)PubMed
27.
Zurück zum Zitat E. Sivan, X. Chen, C.J. Homko, E.A. Reece, G. Boden, Longitudinal study of carbohydrate metabolism in healthy obese pregnant women. Diabetes Care 20(9), 1470–1475 (1997)CrossRefPubMed E. Sivan, X. Chen, C.J. Homko, E.A. Reece, G. Boden, Longitudinal study of carbohydrate metabolism in healthy obese pregnant women. Diabetes Care 20(9), 1470–1475 (1997)CrossRefPubMed
28.
Zurück zum Zitat K.B. Lesser, M.W. Carpenter, Metabolic changes associated with normal pregnancy and pregnancy complicated by diabetes mellitus. Semin. Perinatol. 18(5), 399–406 (1994)PubMed K.B. Lesser, M.W. Carpenter, Metabolic changes associated with normal pregnancy and pregnancy complicated by diabetes mellitus. Semin. Perinatol. 18(5), 399–406 (1994)PubMed
29.
Zurück zum Zitat N.F. Butte, J.M. Hopkinson, N. Mehta, J.K. Moon, E.O. Smith, Adjustments in energy expenditure and substrate utilization during late pregnancy and lactation. Am. J. Clin. Nutr. 69(2), 299–307 (1999)PubMed N.F. Butte, J.M. Hopkinson, N. Mehta, J.K. Moon, E.O. Smith, Adjustments in energy expenditure and substrate utilization during late pregnancy and lactation. Am. J. Clin. Nutr. 69(2), 299–307 (1999)PubMed
30.
Zurück zum Zitat A. Kautzky-Willer, R. Prager, W. Waldhausl, G. Pacini, K. Thomaseth, O.F. Wagner et al., Pronounced insulin resistance and inadequate beta-cell secretion characterize lean gestational diabetes during and after pregnancy. Diabetes Care 20(11), 1717–1723 (1997)CrossRefPubMed A. Kautzky-Willer, R. Prager, W. Waldhausl, G. Pacini, K. Thomaseth, O.F. Wagner et al., Pronounced insulin resistance and inadequate beta-cell secretion characterize lean gestational diabetes during and after pregnancy. Diabetes Care 20(11), 1717–1723 (1997)CrossRefPubMed
31.
Zurück zum Zitat P.M. Catalano, E.D. Tyzbir, N.M. Roman, S.B. Amini, E.A. Sims, Longitudinal changes in insulin release and insulin resistance in nonobese pregnant women. Am. J. Obstet. Gynecol. 165(6), 1667–1672 (1991)CrossRefPubMed P.M. Catalano, E.D. Tyzbir, N.M. Roman, S.B. Amini, E.A. Sims, Longitudinal changes in insulin release and insulin resistance in nonobese pregnant women. Am. J. Obstet. Gynecol. 165(6), 1667–1672 (1991)CrossRefPubMed
32.
Zurück zum Zitat K. Eto, B. Tumenbayar, S. Nagashima, F. Tazoe, M. Miyamoto, M. Takahashi et al., Distinct association of serum FGF21 or adiponectin levels with clinical parameters in patients with type 2 diabetes. Diabetes Res. Clin. Pract. 89(1), 52–57 (2010)CrossRefPubMed K. Eto, B. Tumenbayar, S. Nagashima, F. Tazoe, M. Miyamoto, M. Takahashi et al., Distinct association of serum FGF21 or adiponectin levels with clinical parameters in patients with type 2 diabetes. Diabetes Res. Clin. Pract. 89(1), 52–57 (2010)CrossRefPubMed
33.
Zurück zum Zitat X. Zhang, D.C. Yeung, M. Karpisek, D. Stejskal, Z.G. Zhou, F. Liu et al., Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57(5), 1246–1253 (2008)CrossRefPubMed X. Zhang, D.C. Yeung, M. Karpisek, D. Stejskal, Z.G. Zhou, F. Liu et al., Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57(5), 1246–1253 (2008)CrossRefPubMed
34.
Zurück zum Zitat K. Eto, B. Tumenbayar, S. Nagashima, F. Tazoe, M. Miyamoto, M. Takahashi et al., Distinct association of serum FGF21 or adiponectin levels with clinical parameters in patients with type 2 diabetes. Diabetes Res. Clin. Pract. 89(1), 52–57 (2010)CrossRefPubMed K. Eto, B. Tumenbayar, S. Nagashima, F. Tazoe, M. Miyamoto, M. Takahashi et al., Distinct association of serum FGF21 or adiponectin levels with clinical parameters in patients with type 2 diabetes. Diabetes Res. Clin. Pract. 89(1), 52–57 (2010)CrossRefPubMed
35.
Zurück zum Zitat J. Hindricks, T. Ebert, A. Bachmann, S. Kralisch, U. Lössner, J. Kratzsch et al., Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction. Clin Endocrinol (Oxf). 80, 918–924 (2014)CrossRefPubMed J. Hindricks, T. Ebert, A. Bachmann, S. Kralisch, U. Lössner, J. Kratzsch et al., Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction. Clin Endocrinol (Oxf). 80, 918–924 (2014)CrossRefPubMed
36.
Zurück zum Zitat H. Li, Y. Bao, A. Xu, X. Pan, J. Lu, H. Wu et al., Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. J. Clin. Endocrinol. Metab. 94, 2151–2156 (2009)CrossRefPubMed H. Li, Y. Bao, A. Xu, X. Pan, J. Lu, H. Wu et al., Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. J. Clin. Endocrinol. Metab. 94, 2151–2156 (2009)CrossRefPubMed
37.
Zurück zum Zitat J.C. Pickup, Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27(3), 813–823 (2004)CrossRefPubMed J.C. Pickup, Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27(3), 813–823 (2004)CrossRefPubMed
38.
Zurück zum Zitat B. Vozarova, C. Weyer, R.S. Lindsay, R.E. Pratley, C. Bogardus, P.A. Tataranni, High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51(2), 455–461 (2002)CrossRefPubMed B. Vozarova, C. Weyer, R.S. Lindsay, R.E. Pratley, C. Bogardus, P.A. Tataranni, High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51(2), 455–461 (2002)CrossRefPubMed
39.
Zurück zum Zitat G.P. Sacks, K. Studena, K. Sargent, C.W. Redman, Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am. J. Obstet. Gynecol. 179(1), 80–86 (1998)CrossRefPubMed G.P. Sacks, K. Studena, K. Sargent, C.W. Redman, Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am. J. Obstet. Gynecol. 179(1), 80–86 (1998)CrossRefPubMed
40.
Zurück zum Zitat M.S. Lee, S.E. Choi, E.S. Ha, S.Y. An, T.H. Kim, S.J. Han et al., Fibroblast growth factor-21 protects human skeletal muscle myotubes from palmitate-induced insulin resistance by inhibiting stress kinase and NF-κB. Metabolism 61(8), 1142–1151 (2012)CrossRefPubMed M.S. Lee, S.E. Choi, E.S. Ha, S.Y. An, T.H. Kim, S.J. Han et al., Fibroblast growth factor-21 protects human skeletal muscle myotubes from palmitate-induced insulin resistance by inhibiting stress kinase and NF-κB. Metabolism 61(8), 1142–1151 (2012)CrossRefPubMed
Metadaten
Titel
Fibroblast growth factor 21 expressions in white blood cells and sera of patients with gestational diabetes mellitus during gestation and postpartum
verfasst von
Si-ming Li
Wen-fei Wang
Li-hong Zhou
Lei Ma
Ying An
Wen-juan Xu
Tian-he Li
Yin-hang Yu
De-shan Li
Yan Liu
Publikationsdatum
01.03.2015
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2015
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0309-8

Weitere Artikel der Ausgabe 2/2015

Endocrine 2/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.